ReviewBreast cancer research : BCR2000
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.
Review in Breast cancer research : BCR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- ZNF217 promotes receptor tyrosine kinase plasticity and AXL-ERK dependency in ovarian cancer.bioRxiv : the preprint server for biology · 2026Article
- Phosphatidylinositol 4,5-bisphosphate drives the formation of EGFR and EphA2 complexes.Science advances · 2024Article
- Sprouty genes regulate activated fibroblasts in mammary epithelial development and breast cancer.Cell death & disease · 2024Article
- Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancerRSC advances · 2024Article
- Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.Breast cancer research and treatment · 2024Article
- A Unified Bayesian Framework for Bi-overlapping-Clustering Multi-omics Data via Sparse Matrix Factorization.Statistics in biosciences · 2023Article
- Biased activation of the receptor tyrosine kinase HER2.Cellular and molecular life sciences : CMLS · 2023Article
- Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.BioMed research international · 2022Review
- Embryonic Programs in Cancer and Metastasis-Insights From the Mammary Gland.Frontiers in cell and developmental biology · 2022Review
- Recombinant immunotoxins development for HER2-based targeted cancer therapies.Cancer cell international · 2021Review
- The role of ErbB4 in cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes.Scientific reports · 2019Article
- Article
- LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.American journal of cancer research · 2018Article
- Breast cancers withOncology letters · 2017Article
- Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology.Functional & integrative genomics · 2017Article
- Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.Oncotarget · 2016Article
- SPRY1 regulates mammary epithelial morphogenesis by modulating EGFR-dependent stromal paracrine signaling and ECM remodeling.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalk.World journal of biological chemistry · 2016Review
- PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop.Oncotarget · 2015Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.